TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reaction after patch removal
Endpoint domain: Adverse events/effects
Primary endpoint: Count of anaerobic bacteria on the fitting surface of denture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in self-reported psychological well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lower body maximal dynamic strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle fiber composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term safety assessment based on Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Obsessive-compulsive disorder related costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fridericia's corrected QT interval (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Body image distortion score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in migraine-related medical and prescription costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PSA ng/mL Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Conversion of Minimal Residual Disease (MRD) to <0.01%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between Pain Index and NRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete adenoma eradication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Human milk lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Score of perceived quality of prenatal care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: saturation in the sigmoid colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: EpCAM expression in ovarian carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse experiences with a severity of Grade 3 or 4
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in central subfield thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change from Baseline in macular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: score of the grid MiniZarit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: score of the EuroQuol scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline severity of hemiplegic shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline Shoulder-Hand-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline NIH Stroke Score Upper limb (Motor Arm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum apelin12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Acquired Blood Stream Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in MVO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in plasma phospholipid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Change in Hepatic Fat Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Monthly Migraine Days at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure from symptomatic hydrocele
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pap test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration (AUClast) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent of predicted Full Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Parasite prevalence and density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adequate clinical and parasitological response (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference between Office Blood Pressure and SPRINT type BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physician subjective assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of successful capsule attachments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Short term complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term reintervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Unbound maximum plasma concentration (Cmax(u))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound area under the concentration-time curve calculated to the last observable concentration at time t (AUC0-t(u))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound Area under the concentration-time curve from time zero to infinity (AUC0-inf(u))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Relative Peak Power (W/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Fatigue Index (%)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Difference in the average scores of threat appraisal at week 8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects with success (change >54% in threat appraisal at week 8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global eye gaze characteristic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feature-specific eye gaze characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Major pathologic response (MPR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Daily Neuropathic Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glasgow Outcome Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cognitive motor interference measured by percent change in walking velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DXA analysis of child adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of intra-carotid opioids and sedatives
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Beta 2 Agonist response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Ongoing pregnancy with fetal heart motion
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in glycated haemoglobin (GlyHb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Monogenic lupus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in score of Turesky Modification of the Quigley-Hein Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Changes in score of Modified Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: cytoplasmic viscosity measurement of red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of PRN Doses of anti-emetics needed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accuracy of coronary hemodynamic indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in number of runners
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: New vascular events
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose, measured by adverse event profile
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of BAY80-6946
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tlast) of BAY80-6946
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indicators of Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microstructural brain tissue changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Simplified Disease Activity Index (SDAI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Stent Migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection rate for gastric premalignant lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent reduction in weekly seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percent of subjects with 50% or greater reduction in weekly seizure frequency (responder-rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Safety and tolerability as assessed by vital signs and laboratory assessments
Endpoint domain: Adverse events/effects
Primary endpoint: ECOG performance scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KPS performance scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Minutes of aerobic activity per day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Minutes of sleep per day
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: one-year functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Severe Asthma Exacerbations Per Participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiac ejection fraction score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perfusion imaging score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Analogue State
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Specificity of PRISM HIV O Plus Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of PRISM HIV O Plus Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA copy number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative conversion rate of HbeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety during peri-operation period
Endpoint domain: Adverse events/effects
Primary endpoint: 20-minute pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in delirium scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported measures of clinical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of survival participants
Endpoint domain: Mortality/survival
Primary endpoint: migraine dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Area Under the Concentration Curve From 0 to Infinity (AUC0-∞) of Laropiprant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Maximum Concentration (Cmax) of Laropiprant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Urinary Excretion of Niacin and Niacin Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax of Nicotinuric Acid (NUA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in diffuse myocardial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: difference in myocardial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: difference in left atrial phasic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Medication adherence rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Onset time of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CPAP treatment compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stool quantification of key bacteria associated with intestinal barrier permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood quantification of key bacteria associated with intestinal barrier permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Rey Auditory Verbal Learning Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sleep
Endpoint domain: Life impact
Primary endpoint: % of Excess Weight Loss (EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental cost per avoided stenosis relapse
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Test performance of digital tomosynthesis and digital mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Oxycodone Oral Solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Controller performance of human ankle joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back pain related dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Back Pain Symptom Bothersomeness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Depressive Cognitions Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Medical Outcomes Short Form Health Survey (SF-12) Physical Health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Medical Outcomes Short Form Health Survey (SF-12) Mental Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to technology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain at rest and on coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of ultrasound in the diagnosis of the abnormal position of the mesenteric vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of pelvic sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: aMMP-8 levels of GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving Antibody Titer ≥1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Hepatitis B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety (toxicity) - Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaginal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb hemodynamics (Ankle Brachial Index or Great Toe Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: loco-regional control rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic benefit of MR reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GERD-HRQL Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knee injury and Osteoarthritis Outcome (KOOS) pain subdomain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum Hemorrhage (PPH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of first variceal bleed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Completely cured subjects
Endpoint domain: Mortality/survival
Primary endpoint: Defect fill at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma control test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in TOI and THI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased incidence of Overactive Bladder (OAB) measured by Ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increased incidence of Overactive Bladder (OAB) measured by Questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants with major adverse cardiac events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Number of Combined Unique Active Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUSCAN hand disability score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cognitive performance changes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in VOMS Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Curve (AUC) for BZA, total estrone and total equilin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for BZA, total estrone and total equilin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of function as measured by Hemophilia Activities List (HAL) and Work Productivity and Activity Impairment Scale (WPAI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Quality of Life as measured by EuroQol-5 Dimension questionnaire (EQ5D), Short Form Health Survey (SF-12), and Hemophilia Quality of Life Measure for Adults (HAEMO-QoL-A)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of satisfaction as measured by Hemophilia Treatment Satisfaction Questionnaire (Hemo-SAT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cellular protection of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time From Beginning of Induction to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proportion of successes at 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteomic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline functional performance at six weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline body balance at six weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline upper-body muscular strength at six weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline lower-body muscular strength at six weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline breathing pattern at six weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Speech characteristics post laryngectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallowing characteristics post laryngectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttreatment Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes